# Junta clínica — PT-pseudo_394e0b8dbeeb (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_394e0b8dbeeb",
  "pid": "PT-pseudo_394e0b8dbeeb",
  "task": 1,
  "psa": 9.2,
  "age": 71,
  "months": 3,
  "pirads": "4",
  "psad": 0.17,
  "psav": 1.1,
  "psap": 10.1,
  "vol": 53.0,
  "dre": "Nodus",
  "bx": "Negative",
  "cspca": 0.78939086,
  "medhx": "Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30), Benign prostatic hyperplasia",
  "meds": "atorvastatin, simvastatin, rosuvastatin, aspirin 80 mg, metoprolol, tamsulosin",
  "notes": "PSA 9.2 ng/mL. PI-RADS 4. PSAD 0.17. Prostate volume 53 mL. DRE nodus. csPCa 0.79.",
  "pmhx": [
    "Hypercholesterolaemia",
    "Coronary artery disease",
    "Obesity (BMI >30)",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "93 kg",
    "height": "164 cm",
    "bmi": "34.6",
    "bp": "114/71 mmHg",
    "hr": "70 bpm",
    "smoking": "Current smoker (45 pack-yr)",
    "last_dental": "2 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "04 Jan 2025",
  "enc_ref": "Dr. E. Mulder (GP)",
  "enc_type": "Re-evaluation - prior negative biopsy",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Elevated PSA progression alongside a newly identified PI-RADS 4 lesion on multiparametric MRI has necessitated specialist re-assessment."
    },
    {
      "s": "History",
      "t": "Mr X, a 71-year-old harbour pilot (semi-retired), entered initial evaluation in early 2023 following an incidental PSA elevation. Lower urinary tract symptoms remain mild and are currently managed with tamsulosin, yielding an IPSS score of 7. He reports no haematuria or acute urinary retention. Cardiovascular comorbidities encompass coronary artery disease and hypercholesterolaemia, managed through a regimen of atorvastatin, simvastatin, rosuvastatin, aspirin 80 mg, and metoprolol. He is a Current smoker (45 pack-yr) but maintains physical activity by cycling roughly 30 kilometres three times weekly. Obesity (BMI >30) is present. He remains married and lives with his partner. An adult daughter handles his medical correspondence upon request. Aside from the urological investigations, he experiences stable bilateral knee discomfort stemming from years of deck work and recently visited a podiatrist for routine nail care. No systemic symptoms or unexplained weight loss are reported."
    },
    {
      "s": "Physical examination",
      "t": "DRE — prostate: asymmetrically enlarged, firm texture, discrete nodule palpable in the right mid-gland. General examination remains unremarkable, with stable vital signs and no evidence of palpable lymphadenopathy or abdominal masses."
    }
  ],
  "occupation": "harbour pilot (semi-retired)",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Adult son (primary contact)",
  "recent_other": [
    "Podiatry — routine foot care"
  ],
  "alcohol": "8 units / week",
  "exercise": "Cycling 3x/week, ~30 km",
  "ipss": "IPSS score: 7/35 (mild LUTS)",
  "admin": "Daughter manages communication; CC on letters with patient consent.",
  "mri_hospital": "Jeroen Bosch Ziekenhuis ('s-Hertogenbosch)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_394e0b8dbeeb
Task: 1

Encounter: Urology - outpatient on 04 Jan 2025.
Referrer: Dr. E. Mulder (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 71-year-old male
  - PSA: 9.2 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.17 ng/mL²
  - PSA velocity: 1.1 ng/mL/yr
  - Prior PSA: 10.1 ng/mL
  - Prostate volume: 53.0 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.78939086 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30), Benign prostatic hyperplasia
  - Problem list / PMHx: Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30), Benign prostatic hyperplasia
  - Current medication: atorvastatin, simvastatin, rosuvastatin, aspirin 80 mg, metoprolol, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 9.2 ng/mL. PI-RADS 4. PSAD 0.17. Prostate volume 53 mL. DRE nodus. csPCa 0.79.

Vitals: weight 93 kg, height 164 cm, BMI 34.6, BP 114/71 mmHg, HR 70 bpm. Smoking: Current smoker (45 pack-yr).

Chief complaint: Elevated PSA progression alongside a newly identified PI-RADS 4 lesion on multiparametric MRI has necessitated specialist re-assessment.

History: Mr X, a 71-year-old harbour pilot (semi-retired), entered initial evaluation in early 2023 following an incidental PSA elevation. Lower urinary tract symptoms remain mild and are currently managed with tamsulosin, yielding an IPSS score of 7. He reports no haematuria or acute urinary retention. Cardiovascular comorbidities encompass coronary artery disease and hypercholesterolaemia, managed through a regimen of atorvastatin, simvastatin, rosuvastatin, aspirin 80 mg, and metoprolol. He is a Current smoker (45 pack-yr) but maintains physical activity by cycling roughly 30 kilometres three times weekly. Obesity (BMI >30) is present. He remains married and lives with his partner. An adult daughter handles his medical correspondence upon request. Aside from the urological investigations, he experiences stable bilateral knee discomfort stemming from years of deck work and recently visited a podiatrist for routine nail care. No systemic symptoms or unexplained weight loss are reported.

Physical examination: DRE — prostate: asymmetrically enlarged, firm texture, discrete nodule palpable in the right mid-gland. General examination remains unremarkable, with stable vital signs and no evidence of palpable lymphadenopathy or abdominal masses.

Patient info: harbour pilot (semi-retired); Married; Lives with partner.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 8 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Podiatry — routine foot care.
Admin: Daughter manages communication; CC on letters with patient consent.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.82
  uncertainty  +/- 0.09 epistemic (95% band 0.64-1.00); among patients I cannot tell apart the outcome was 0.67 of 1.00 mixed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior negative biopsy. My criterion answers BIOPSY.

The criterion: repeat, targeted, when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for an unchanged PI-RADS 3 or lower picture. In the labelled series this criterion matched the reading urologist in 16 of 18 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 18 labelled men in this same situation (Negative prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.00 — IDENTICAL PANEL: this is the same case, already in the labelled series: PI-RADS 4, PSA 9.2, PSAD 0.17, age 71, DRE Nodus -> BIOPSY (clear). He wrote: "P4 in 71 Y old patient with positive DRE"
  2. distance 1.41: PI-RADS 4, PSA 12.0, PSAD 0.313, age 73, DRE Not done -> BIOPSY (clear). He wrote: "P4 in 73 year old patient."
  3. distance 1.95: PI-RADS 4, PSA 6.0, PSAD 0.08, age 67, DRE Normal -> BIOPSY (clear). He wrote: "P4 lesion in 67 year old patient."

PRECEDENT: BIOPSY. The nearest precedent is this very patient, so the library returns what the reading urologist actually did with him. That is a record, not a judgement; out of sample this expert is worth only what the distance is worth.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. This patient is in the labelled series, so what follows is the reading urologist's own trace for him, not a prediction.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: psad=noted, dre=important, psa=important, bx=noted, comorbidity=noted, fh=noted, vol=noted, age=important, pirads=decisive.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a repeat biopsy after a negative systematic biopsy should be considered dependent on risk factors such as PSA density, PSA velocity, and the PI-RADS score. The guideline suggests that low PSA-D (< 0.15 ng/mL/cc) and low PSA velocity (PSAV) may be factors to exclude a repeat biopsy.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not settled by the guideline because the guideline makes the decision dependent on specific laboratory values like PSA density and PSA velocity. Expert 1's reliance on panel variables alone does not satisfy the guideline's requirement for these specific quantitative metrics.

WHAT WE STILL NEED
The guideline requires the PSA density and PSA velocity to determine the decision.
PSA density is 0.17 ng/mL/cc, which is above the threshold of 0.15 ng/mL/cc mentioned in the retrieved text.
PSA velocity is 1.1 ng/mL/yr, which is not explicitly compared against a threshold in the retrieved text.
The prior biopsy status is Negative, which is a known fact on the panel, which is relevant as the guideline discusses follow-up after a negative biopsy.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on whether the quantitative metrics of PSA density and velocity, as per the EAU guidelines, are sufficient to override the general cohort consensus and the expert panel's suggestion.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone of the PI-RADS 4 lesion?
  psa_trend (get_psa_trend) -> What is the trend of the serial PSA values beyond the headline value of 9.2 ng/mL?
  previous_notes (get_previous_notes) -> What was the management context regarding the prior negative biopsy, including the number and dates of biopsy sessions and whether a surveillance protocol is in place?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. How should the PSA velocity of 1.1 ng/mL/yr be interpreted in the context of the EAU guideline regarding repeat biopsy decisions?

On the plan itself: Dropped 1 question(s) that asked for a value already printed on the panel: "Given the PSA density of 0.17 ng/mL/cc, does this value alone, in conjunction with the PI-RADS 4 finding, meet the EAU guideline criteria for proceeding with a repeat biopsy?".

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
What is the lesion size and zone of the PI-RADS 4 lesion?
The lesion is a "12 mm hypointense focus within the right mid-gland, reaching toward the peripheral zone."

psa_trend
What is the trend of the serial PSA values beyond the headline value of 9.2 ng/mL?
The trend shows values of "7.0" on "Apr 2023", "7.9" on "Nov 2023", "6.5" on "Jun 2024", and "9.2" on "Jan 2025".

previous_notes
What was the management context regarding the prior negative biopsy, including the number and dates of biopsy sessions and whether a surveillance protocol is in place?
The management context involved an "Initial laboratory workup in April 2023 flagged a PSA elevation of 6.1 ng/mL," followed by a "repeat multiparametric MRI that located a suspicious focus." The patient had a "previous negative biopsy" and specialist input was requested for re-assessment.

WHAT I DID NOT OPEN
family-history anamnesis, because the clinical decision hinges on the quantitative metrics and prior workup details already retrieved.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now
PI-RADS 4 lesion identified on mpMRI.
PSA density of "0.17 ng/mL/mL", which is above the threshold of "0.15 ng/mL/cc" mentioned in the retrieved EAU guideline text.

Findings that argue AGAINST sampling this patient now
PSA velocity of "1.1 ng/mL/yr" is not explicitly compared against a threshold in the retrieved EAU guideline text.

WHERE THIS LEANS
The quantitative metrics, particularly the PSA density, suggest a leaning towards proceeding with further investigation, which aligns with the expert panel's suggestion.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 9.20 ng/mL over 4 points spanning 21 months; velocity +0.89 ng/mL per year; doubling time about 78 months.
PROJECTION at 6 months: 14.3 ng/mL, conformal 95% band 4.1-49.8.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.78
  uncertainty  +/- 0.10 epistemic (95% band 0.59-0.97), of which 0.01 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 89% of the time over the 37 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.82  ('firm' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.78  ('firm' tier, fusion_nolab)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=1.00  (identical panel in the series)
  EXPERT-COHORT      BIOPSY  (rule pirads_ge_4)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: identical precedent in the labelled series — carried by EXPERT-LIBRARY.
PANEL ANSWER: BIOPSY. The labelled series contains this exact panel; the library returns the reading urologist's own decision for it. Out of sample this rung never fires.

Confidence the trace model expects here: clear. Weights it expects: psad=noted, dre=important, psa=important, bx=noted, comorbidity=noted, fh=noted, vol=noted, age=important, pirads=decisive.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology_report, psa_trend, and previous_notes—address the core elements of the open questions. The registrar retrieved the lesion size from the radiology report, the PSA trend, and the management context regarding the prior negative biopsy.

ALIGNMENT WITH THE PANEL
The retrieved evidence supports the PANEL-PROTOCOL's answer of BIOPSY. Specifically, the registrar found a PI-RADS 4 lesion and a PSA density of 0.17 ng/mL/mL, which the registrar noted supports proceeding with further investigation.

THE OPEN QUESTIONS, ONE BY ONE
Q1. How should the PSA velocity of 1.1 ng/mL/yr be interpreted in the context of the EAU guideline regarding repeat biopsy decisions? The retrieved documents do not contain a direct interpretation of this velocity against the EAU threshold.

WHAT CARRIES WEIGHT, AND WHY
The most relevant variables are the PI-RADS 4 finding, the PSA density of 0.17 ng/mL/mL, and the prior negative biopsy status. These matter because the EAU guideline explicitly links repeat biopsy decisions to PSA density and velocity, and the PI-RADS score is a primary driver for suspicion.

MY SUGGESTION TO THE CHAIR
Given that the PSA density exceeds the EAU threshold mentioned in the retrieved guideline text, I suggest proceeding with a biopsy. This aligns with the expert panel's consensus and the findings retrieved by the registrar.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Given the patient has a PI-RADS 4 lesion identified on MRI and a prior negative biopsy, a repeat targeted biopsy is indicated. This decision is supported by the cohort criterion and the expert panel consensus, which is further reinforced by the registrar retrieving the PI-RADS 4 finding and the PSA density of 0.17 ng/mL/mL, which exceeds the EAU threshold. The evidence converged clearly toward proceeding with further investigation.

What carried weight: psad=noted, psa=important, bx=noted, comorbidity=noted, vol=noted, age=important, pirads=decisive
Documents this conference opened: radiology_report, psa_trend, previous_notes
